您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > LSKL,Inhibitor of Thrombospondin(TSP-1)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LSKL,Inhibitor of Thrombospondin(TSP-1)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LSKL,Inhibitor of Thrombospondin(TSP-1)图片
CAS NO:283609-79-0
包装与价格:
包装价格(元)
2 mg电议
5 mg电议
10 mg电议
25 mg电议
50 mg电议
100 mg电议
1 mL*10 mM(in DMSO)电议

产品名称
LSKL, Inhibitor of Thrombospondin TSP-1
LSKL, 血小板反应蛋白抑制剂 (TSP-1)
产品介绍
LSKL, Inhibitor of Thrombospondin TSP-1 是一种竞争性的TGF-β1拮抗剂,是一种衍生自 LAP-TGFβ 的四肽。它能够抑制TSP-1介导的TGF-β1活性来抑制蛛网膜下纤维化,防止慢性脑积水的发生并改善蛛网膜下腔出血后的长期神经认知缺陷。

产品描述

LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β.

体内活性

The protective effects of the LSKL peptide were achieved via the inhibition of TGF-β1 activity and subsequent Smad2/3 signaling.?The LSKL peptide may improve long-term neurocognitive deficits after SAH.?The LSKL peptide suppresses subarachnoid fibrosis via inhibition of TSP1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following SAH[1].Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight[2].

动物实验

Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy[2].

Cas No.

283609-79-0

分子式

C21H42N6O5

分子量

458.6

别名

LSKL, Inhibitor of Thrombospondin TSP-1;LSKL, 血小板反应蛋白抑制剂 (TSP-1)

储存和溶解度

DMSO:100 mg/mL (218.05 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years